Scientists developed an antibody (15B6) that bound next to the membrane at the protease-sensitive region, did not bind to shed mesothelin, and made CAR-T cells that had much higher anti-tumor activity than a CAR-T that binds to shed mesothelin.
[Proceedings Of The National Academy Of Sciences Of The United States Of America]